Being faithful to our management philosophy, we carry out licensing activities with the motto of sincerity and trust.
Since the current chairman, Dr. Imanishi, visited Taiwan Research Institute of Bristol Myers Squibb (established in Suncheon Pharmaceutical Headquarters) in 1967 for guidance, he built strong relations with Taiwanese bioindustry companies and public research institutes. We have taken over Dr. Imanishi's personal connections and are further developing those intimate relationships.
We also collect licensing information through our network of affiliated companies (Taiwan, South Korea, Europe, and the United States).
We are introducing licensing candidates such as biosimilars, biobetters, new synthetic compounds, and new generic drugs. We do not specify the therapeutic area but collect candidates with an emphasis on novelty.
To date, we have introduced products relating to malignant tumors, cell therapy, digestive organs, respiratory organs, dermatology, fluid diseases, radiology, analgesics, ophthalmology, and platform technologies.
We invite you to contact us to find out more about our activities.
Licensing of medical devices and other medical products
We can introduce new medical devices to license in or distribute in Japan.
Medical devices: machinery and appliances used for diagnosis, treatment and prevention for humans and animals or
intended to treat the body structure and function.
We are in strict compliance with all related laws (Pharmaceuticals and Medical Devices Act.)
Other medical products: Medical products other than medical devices, pharmaceuticals and diagnostics
Licensing of functional foods
We introduce candidates for functional foods in various fields from overseas.